Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
28 Jan 2022
28 Jan 2022
Historique:
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
29
1
2022
Statut:
ppublish
Résumé
To characterize the epidemiological properties of the B.1.526 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) variant of interest, here we used nine epidemiological and population datasets and model-inference methods to reconstruct SARS-CoV-2 transmission dynamics in New York City, where B.1.526 emerged. We estimated that B.1.526 had a moderate increase (15 to 25%) in transmissibility, could escape immunity in 0 to 10% of previously infected individuals, and substantially increased the infection fatality risk (IFR) among adults 65 or older by >60% during November 2020 to April 2021, compared to estimates for preexisting variants. Overall, findings suggest that new variants like B.1.526 likely spread in the population weeks before detection and that partial immune escape (e.g., resistance to therapeutic antibodies) could offset prior medical advances and increase IFR. Early preparedness for and close monitoring of SARS-CoV-2 variants, their epidemiological characteristics, and disease severity are thus crucial to COVID-19 (coronavirus disease 2019) response.
Identifiants
pubmed: 35089794
doi: 10.1126/sciadv.abm0300
pmc: PMC8797779
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabm0300Subventions
Organisme : NIAID NIH HHS
ID : R01 AI145883
Pays : United States
Références
Nature. 2021 Sep;597(7878):703-708
pubmed: 34428777
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Public Health Rep. 2017 Jul/Aug;132(1_suppl):23S-30S
pubmed: 28692384
Cell. 2021 May 13;184(10):2587-2594.e7
pubmed: 33861950
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):712-716
pubmed: 33983915
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Lancet Infect Dis. 2021 Feb;21(2):203-212
pubmed: 33091374
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17209-14
pubmed: 12481034
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nat Commun. 2021 Sep 22;12(1):5573
pubmed: 34552095
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
PLoS Comput Biol. 2020 Jun 15;16(6):e1007989
pubmed: 32542015
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Nat Commun. 2021 Aug 9;12(1):4886
pubmed: 34373458
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Lancet Infect Dis. 2020 Jul;20(7):793-802
pubmed: 32247326
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252